Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.4K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Common Clonal Origin of Core-Binding-Factor AML in Both Donor and Recipient Following Kidney Transplantation.

Case reports in hematology·2026
Same author

Anti-thymocyte globulin-based treatment frequently leads to enduring treatment success in both old and young adult patients with aplastic anaemia: a real-world analysis from the Dutch aplastic anaemia registry.

Annals of hematology·2026
Same author

Clonal haematopoiesis associates with distinct cytometric changes of red blood cells and platelets.

British journal of haematology·2025
Same author

Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes: the HOVON89 trial.

Leukemia·2024
Same author

Good manufacturing practice production of CD34<sup>+</sup> progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia.

Cancer immunology, immunotherapy : CII·2023

Related Experiment Video

Updated: Oct 6, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K

Genetic diversity within leukemia-associated immunophenotype-defined subclones in AML.

F Tiso1, T N Koorenhof-Scheele1, E Huys1

  • 1Department of Laboratory Medicine, Laboratory of Hematology, Radboudumc, Nijmegen, The Netherlands.

Annals of Hematology
|January 13, 2022
PubMed
Summary
This summary is machine-generated.

Combining immunophenotyping and genetic sequencing in acute myeloid leukemia (AML) provides a more complete understanding of the disease. These complementary techniques reveal crucial details about malignant cell populations that single methods may miss.

Keywords:
AMLImmunophenotypeMRDMolecular diagnostics

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.6K
Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.5K

Related Experiment Videos

Last Updated: Oct 6, 2025

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.2K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.6K
Characterizing Mutational Load and Clonal Composition of Human Blood
07:58

Characterizing Mutational Load and Clonal Composition of Human Blood

Published on: July 11, 2019

7.5K

Area of Science:

  • Hematology
  • Molecular Biology
  • Cancer Genomics

Background:

  • Acute myeloid leukemia (AML) is a complex blood cancer characterized by significant heterogeneity and clonal evolution.
  • Understanding the genetic makeup of distinct leukemic subclones is crucial for effective treatment strategies.
  • Current diagnostic approaches often rely on immunophenotyping and genetic analysis, but their combined utility in characterizing AML subclones is not fully elucidated.

Purpose of the Study:

  • To investigate the complementary roles of immunophenotyping and error-corrected sequencing of driver genes in characterizing distinct subclones within AML patients.
  • To determine if combining these techniques provides a more comprehensive view of disease heterogeneity and clonal architecture compared to using either method alone.

Main Methods:

  • Error-corrected sequencing of 27 myeloid leukemia driver genes was performed on 86 FACS-sorted normal and aberrant cell fractions from 10 AML patients.
  • Immunophenotypic characterization was conducted on the same cell fractions to identify distinct subfractions.
  • Comparative analysis was performed to assess the information gained from each technique and their combination.

Main Results:

  • Three scenarios were identified: 1) both techniques equally characterized the malignancy, 2) immunophenotyping missed genetically aberrant subclones, and 3) genetic analysis missed mutations present in immunophenotypically defined malignant populations.
  • In several cases, immunophenotypically normal-appearing cells harbored significant genetic mutations, highlighting the limitations of relying solely on immunophenotyping.
  • Conversely, some immunophenotypically defined malignant populations lacked detectable mutations via sequencing, indicating potential limitations in genetic analysis sensitivity or clonal representation.

Conclusions:

  • Immunophenotyping and molecular genetic analyses offer complementary information for characterizing acute myeloid leukemia.
  • A parallel application of both immunophenotyping and molecular techniques is recommended for a comprehensive understanding of AML heterogeneity and clonal evolution.
  • Integrating these approaches can lead to more accurate disease assessment and potentially improved therapeutic decisions in AML management.